ISL1+ Multipotent Progenitor Cell Differentiation via Small Molecule Pathway Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating and maintaining multipotent progenitor cells, such as ISL1+ Multipotent Progenitors (IMPs) and CXCR4+ CD56+ cells, are limited in efficiency and scalability, hindering their therapeutic and research applications, particularly in tissue repair and cardiovascular disease treatment.
Innovation Solution
The development of methods to differentiate human pluripotent stem cells, including embryonic stem cells and induced pluripotent stem cells, into ISL1+ IMPs and CXCR4+ CD56+ cells using specific small molecule compounds and signaling pathway inhibitors, enabling the production of stable, self-renewing populations that can home to damaged tissues and differentiate into various cell types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used to generate multipotent progenitor cells, then cell production is possible, but efficiency and scalability are limited
Solution Approach 1:
The patent employs small molecule compounds to modulate signaling pathways (Wnt, BMP, Activin/Nodal) by changing biochemical parameters such as pathway activation states and gene expression levels. This enables controlled differentiation of pluripotent stem cells into multipotent progenitor cells with improved efficiency and scalability compared to conventional methods
Solution Approach 2:
Small molecule compounds serve as intermediaries that mediate the differentiation process by targeting specific signaling pathways. These molecules enable precise control over cell fate decisions without requiring complex viral transduction or direct genetic manipulation, thereby improving manufacturing scalability
2Reliability
If pluripotent stem cells are differentiated into multipotent progenitor cells, then therapeutic applications are enabled, but differentiation efficiency is limited
Solution Approach 1:
The differentiation process is segmented into distinct stages targeting specific signaling pathways (Wnt inhibition, BMP activation, Activin/Nodal inhibition). Each pathway modulation represents a discrete step that can be independently optimized, improving overall differentiation efficiency while maintaining therapeutic reliability
Solution Approach 2:
The patent applies preliminary inhibition of specific signaling pathways (Wnt, Activin/Nodal) before initiating differentiation. This pre-conditioning of the cellular environment prepares pluripotent stem cells for efficient conversion into multipotent progenitor cells, enhancing both differentiation efficiency and therapeutic applicability
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
The present invention relates to inter alia, methods for the generation and maintenance of Mesoderm-derived ISL 1+ Multipotent Progenitors (IMPs), the production of a number of pluripotent cells including and epicardial pluripotent cells (EPCs) and using these cells to produce endothelial cells, cardiomyocytes, smooth muscle cells, vascular cells and other cells and related methods as otherwise disclosed herein. The invention also relates to compositions comprising a population of cells.